Page 110 - MI-1-1

Microbes & Immunity Factors associated with response to T-VEC

Simpson, Peter Callas, Conor O’Neill, Mirabelle 5. Ribas A, Dummer R, Puzanov I, et al. Oncolytic
Sajisevi, Jessica Cintolo-Gonzalez virotherapy promotes intratumoral T cell infiltration
Methodology: Michela Salusti-Simpson, Conor O’Neill, and improves Anti-PD-1 immunotherapy. Cell. 2017;
Mirabelle Sajisevi, Jessica Cintolo-Gonzalez 170(6):1109-1119.e10.
Writing – original draft: Anupama Balasubramanian, doi: 10.1016/j.cell.2017.08.027
Michela Salusti-Simpson, Peter Callas 6. Carr MJ, Sun J, DePalo D, et al. Talimogene laherparepvec
Writing – review & editing: Anupama Balasubramanian, (T-VEC) for the treatment of advanced locoregional
Peter Callas, Conor O’Neill, Hibba Rehman, Shahid melanoma after failure of immunotherapy: An international
Ahmed, Mirabelle Sajisevi, Christopher J. Anker, multi-institutional experience. Ann Surg Oncol.
Jessica Cintolo-Gonzalez 2022;29(2):791-801.

Ethics approval and consent to participate doi: 10.1245/s10434-021-10910-5
7. Hu-Lieskovan S, Moon J, Hyngstrom J, et al. Abstract 3275:
Ethics approval was obtained from the Institutional Review Combination of talimogene laherparepvec (T-VEC)
Board of the University of Vermont (STUDY00002113). with pembrolizumab (pembro) in advanced melanoma
Written and verbal patient consent was obtained for patients following progression on a prior PD-1 inhibitor:
participation in the study. SWOG S1607. Cancer Res. 2023;83(7 Suppl):3275.

Consent for publication doi: 10.1158/1538-7445.AM2023-3275
Written and verbal patient consent was obtained for 8. Van Akkooi AC, Haferkamp S, Papa S, et al. A retrospective
chart review study of real-world use of talimogene
publication of the study.
laherparepvec in unresectable stage IIIB-IVM1a melanoma
Availability of data in four European countries. Adv Ther. 2021;38(2):1245-1262.
doi: 10.1007/s12325-020-01590-w
Data used in the study is available on request.
9. Ressler JM, Karasek M, Koch L, et al. Real-life use of
Further disclosure talimogene laherparepvec (T-VEC) in melanoma patients in
centers in Austria, Switzerland and Germany. J Immunother
Partial results of this manuscript were presented at the Cancer. 2021;9(2):e001701.
Advanced Cancer Therapies Conference in San Diego,
California, in February 2023. doi: 10.1136/jitc-2020-001701
10. Dummer R, Gyorki DE, Hyngstrom J, et al. Neoadjuvant
References talimogene laherparepvec plus surgery versus surgery alone
for resectable stage IIIB-IVM1a melanoma: A randomized,
1. Puzanov I, Milhem MM, Minor D, et al. Talimogene
laherparepvec in combination with ipilimumab in open-label, phase 2 trial. Nat Med. 2021;27(10):1789-1796.
previously untreated, unresectable stage IIIB-IV melanoma. doi: 10.1038/s41591-021-01510-7
J Clin Oncol. 2016;34(22):2619-2626.
11. Muilenburg DJ, Beasley GM, Thompson ZJ, Lee JH,
doi: 10.1200/JCO.2016.67.1529 Tyler DS, Zager JS. Burden of Disease predicts response to
isolated limb infusion with melphalan and actinomycin D in
2. Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene
laherparepvec improves durable response rate in patients with melanoma. Ann Surg Oncol. 2015;22(2):482-488.
advanced melanoma. J Clin Oncol. 2015;33(25):2780-2788. doi: 10.1245/s10434-014-4072-0
doi: 10.1200/JCO.2014.58.3377 12. Amin MB, Greene FL, Edge SB, et al. The eighth edition
AJCC cancer staging manual: Continuing to build a bridge
3. Harrington KJ, Andtbacka RH, Collichio F, et al. Efficacy
and safety of talimogene laherparepvec versus granulocyte- from a population-based to a more “personalized” approach
macrophage colony-stimulating factor in patients with stage to cancer staging. CA Cancer J Clin. 2017;67(2):93-99.
IIIB/C and IVM1a melanoma: Subanalysis of the Phase III doi: 10.3322/caac.21388
OPTiM trial. Onco Targets Ther. 2016;9:7081-7093.
13. Franke V, Berger DM, Klop WM, et al. High response rates for
doi: 10.2147/OTT.S115245 T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a).
Int J Cancer. 2019;145(4):974-978.
4. Chesney JA, Ribas A, Long GV, et al. Randomized, double-
blind, placebo-controlled, global phase III trial of talimogene doi: 10.1002/ijc.32172
laherparepvec combined with pembrolizumab for advanced 14. Louie RJ, Perez MC, Jajja MR, et al. Real-World outcomes
melanoma. J Clin Oncol. 2023;41(3):528-540.
of talimogene laherparepvec therapy: A multi-institutional
doi: 10.1200/JCO.22.00343 experience. J Am Coll Surg. 2019;228(4):644-649.

Volume 1 Issue 1 (2024) 104 doi: 10.36922/mi.3445